AAAAAA
Results:
1-14
|
Results: 14
Authors:
BACKMAN JT
SIEGLE I
FRITZ P
Citation: Jt. Backman et al., IMMUNOHISTOCHEMICAL LOCALIZATION OF METALLOTHIONEIN IN SYNOVIAL TISSUE OF PATIENTS WITH CHRONIC INFLAMMATORY AND DEGENERATIVE JOINT DISEASE, Virchows Archiv, 433(2), 1998, pp. 153-160
Authors:
BACKMAN JT
KIVISTO KT
OLKKOLA KT
NEUVONEN PJ
Citation: Jt. Backman et al., THE AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE FOR ORAL MIDAZOLAMIS 400-FOLD LARGER DURING TREATMENT WITH ITRACONAZOLE THAN WITH RIFAMPICIN, European Journal of Clinical Pharmacology, 54(1), 1998, pp. 53-58
Authors:
BACKMAN JT
SIEGLE I
FRITZ P
Citation: Jt. Backman et al., QUANTITATIVE IMMUNOHISTOCHEMICAL ASSESSMENT OF METALLOTHIONEIN IN SYNOVIAL-MEMBRANE OF PATIENTS WITH INFLAMMATORY AND DEGENERATIVE JOINT DISEASE, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 576-576
Authors:
MURDTER TE
SPERKER B
BACKMAN JT
FRIEDEL G
MCCLELLAN M
FRITZ P
BOSSLER K
KROEMER HK
Citation: Te. Murdter et al., BETA-GLUCURONIDASE EXPRESSION, ACTIVITY, AND LOCALIZATION OF IN HUMANLUNG-CANCER - A BASE FOR DRUG TARGETING, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4518-4518
Authors:
SIEGLE I
KLEIN T
BACKMAN JT
SAAL JG
NUSING RM
FRITZ P
Citation: I. Siegle et al., EXPRESSION OF CYCLOOXYGENASE-1 AND CYCLOOXYGENASE-2 IN HUMAN SYNOVIALTISSUE - DIFFERENTIAL ELEVATION OF CYCLOOXYGENASE-2 IN INFLAMMATORY JOINT DISEASES, Arthritis and rheumatism, 41(1), 1998, pp. 122-129
Authors:
SPERKER B
BACKMAN JT
KROEMER HK
Citation: B. Sperker et al., THE ROLE OF BETA-GLUCURONIDASE IN DRUG DISPOSITION AND DRUG TARGETINGIN HUMANS, Clinical pharmacokinetics, 33(1), 1997, pp. 18-31
Authors:
VILLIKKA K
KIVISTO KT
BACKMAN JT
OLKKOLA KT
NEUVONEN PJ
Citation: K. Villikka et al., TRIAZOLAM IS INEFFECTIVE IN PATIENTS TAKING RIFAMPIN, Clinical pharmacology and therapeutics, 61(1), 1997, pp. 8-14
Authors:
BACKMAN JT
OLKKOLA KT
OJALA M
LAAKSOVIRTA H
NEUVONEN PJ
Citation: Jt. Backman et al., CONCENTRATIONS AND EFFECTS OF ORAL MIDAZOLAM ARE GREATLY REDUCED IN PATIENTS TREATED WITH CARBAMAZEPINE OR PHENYTOIN, Epilepsia, 37(3), 1996, pp. 253-257
Authors:
BACKMAN JT
OLKKOLA KT
NEUVONEN PJ
Citation: Jt. Backman et al., RIFAMPIN DRASTICALLY REDUCES PLASMA-CONCENTRATIONS AND EFFECTS OF ORAL MIDAZOLAM, Clinical pharmacology and therapeutics, 59(1), 1996, pp. 7-13
Authors:
BACKMAN JT
OLKKOLA KT
NEUVONEN PJ
Citation: Jt. Backman et al., AZITHROMYCIN DOES NOT INCREASE PLASMA-CONCENTRATIONS OF ORAL MIDAZOLAM, International journal of clinical pharmacology and therapeutics, 33(6), 1995, pp. 356-359
Authors:
ARANKO K
LUURILA H
BACKMAN JT
NEUVONEN PJ
OLKKOLA KT
Citation: K. Aranko et al., THE EFFECT OF ERYTHROMYCIN ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ZOPICLONE, British journal of clinical pharmacology, 38(4), 1994, pp. 363-367
Authors:
BACKMAN JT
OLKKOLA KT
ARANKO K
HIMBERG JJ
NEUVONEN PJ
Citation: Jt. Backman et al., DOSE OF MIDAZOLAM SHOULD BE REDUCED DURING DILTIAZEM AND VERAPAMIL TREATMENTS, British journal of clinical pharmacology, 37(3), 1994, pp. 221-225
Authors:
BACKMAN JT
ARANKO K
HIMBERG JJ
OLKKOLA KT
Citation: Jt. Backman et al., A PHARMACOKINETIC INTERACTION BETWEEN ROXITHROMYCIN AND MIDAZOLAM, European Journal of Clinical Pharmacology, 46(6), 1994, pp. 551-555
Authors:
OLKKOLA KT
BACKMAN JT
NEUVONEN PJ
Citation: Kt. Olkkola et al., MIDAZOLAM SHOULD BE AVOIDED IN PATIENTS RECEIVING THE SYSTEMIC ANTIMYCOTICS KETOCONAZOLE OR ITRACONAZOLE, Clinical pharmacology and therapeutics, 55(5), 1994, pp. 481-485
Risultati:
1-14
|